Pharmaceuticals
AVCJ Awards 2019: Exit of the Year - IPO: Innovent Biologics
Innovent Biologics has set a new standard for Chinese biotech, securing an innovative drug development tie-up with Eli Lilly and then completing a successful Hong Kong listing
China's I-Mab falls on US debut after $104m IPO
China-based I-Mab Biopharma traded as much as 12% lower than initial pricing following the private equity-backed company’s $104 million IPO in the US.
China's Transcenta secures $100m funding round
Transcenta Holding, a Chinese biotech company formed last year through the merger of MabSpace Bioscience and Hangzhou Just Biotherapeutics (HJB), has raised $100 million in an extended Series B funding round.
Chinese drug developer wins General Atlantic backing
General Atlantic has led a $69 million Series D round of funding for Adagene, a Chinese drug developer with one cancer treatment currently in phase one clinical trials in China and the US.
Everstone backs US, India-based generics developer
The Everstone Group has agreed to invest $50 million in Slayback Pharma, a developer of generic and specialty drugs with a presence in India and the US.
India's True North makes $75m biosimilars bet
True North has invested INR5.36 billion ($74.6 million) in the biosimilars business of India-listed pharmaceuticals giant Biocon.
Chinese biopharma player secures $100m Series B
Elpiscience, a Shanghai-based biopharmaceutical company has completed a $100 million Series B round of funding led by specialist healthcare GP Hyfinity Investments.
China's KeChow Pharma gets $45m Series C
Shanghai Kechow Pharma, a Chinese small molecule targeted drug developer, has raised a $45 million Series C round led by Decheng Capital.
Deal focus: EQT fulfills Laobaixing's prescription
EQT spent 11 years helping Chinese pharmacy chain Laobaixing evolve from large-format laggard into a focused and efficient operator that meets the needs of modern customers. It has now exited with a 7.7x return
China-Australia biotech fund raises $31m
UniSA Ventures, a tech commercialization unit of the University of South Australia, has secured A$45 million ($31 million) from a group of Chinese investors for an Australia-focused biotechnology fund.
Local GPs commit $71m to China biotech player
EOC Pharma, a Chinese biotech developer focused on cancer treatments, has closed a RMB500 million ($71 million) Series C round raised from a group of local private equity investors.
Chinese biopharma start-up raises $43m Series B
Chinese cancer and autoimmune disease therapy developer Clover Biopharmaceuticals has raised a $43 million Series B round led by local VC Lapam Capital and US private equity firm Delos Capital.
FountainVest, Primavera invest $557m in China pharmacy chain
FountainVest Partners and Primavera Capital have paid $557 million for a 24.78% stake in Chinese pharmacy chain Laobaixing. It will provide a full exit for EQT Partners.
China’s Genetron secures $50m Series D, seeks US IPO
Genetron Holdings, a precision oncology technology developer in China, has raised a $50 million Series D round and filed for a US IPO.
Chinese cancer database provider secures $140m
Medbanks, a Chinese oncology database platform, has raised around RMB1 billion ($140 million) in an extended Series D funding round led by Tencent Holdings and Wu Capital.
Advent buys Indian biopharma player
Advent International has agreed to acquire a controlling position in Bharat Serums and Vaccines, an Indian biopharmaceuticals supplier focused on the women’s health segment.
CICC, AstraZeneca launch $1b China healthcare fund
China International Capital Corporation (CICC) and global pharmaceutical giant AstraZeneca are looking to raise $1 billion for a fund that will back Chinese healthcare companies as well as international players looking to enter the country.
Chinese antibody drug developer raises $150m
Akeso Biopharma, a Chinese biotech company specializing in antibody drugs, has raised a $150 million Series D round led by Loyal Valley Capital and Sino Biopharm.
China's I-Mab Biopharma pursues US IPO
I-Mab Biopharma, the product of a CBC Group-engineered merger of two Chinese drug developers, has announced plans for a NASDAQ IPO.
Biotech player Ascentage gains on debut after $53m HK IPO
Ascentage Pharma saw its share price surge 57% during the first day of trading in Hong Kong before closing up 9.9%, following a heavily oversubscribed HK$416.6 million ($53 million) IPO.
Goldman leads $62m Series D for China's Fountain Medical
Fountain Medical Development, a China-based contract research organization (CRO) that serves a global client base of drug developers, has received $62 million in Series D funding led by Goldman Sachs.
Merck launches China seed fund
Germany-based life sciences and healthcare technology giant Merck has launched a RMB100 million ($14.1 million) seed fund targeting Chinese start-ups.
Chinese healthcare software provider raises $212m
Taimei Technology, a Chinese cloud-based software provider that serves pharmaceutical companies and clinical research organizations (CROs) has raised RMB1.5 billion ($212 million) through an extended Series E round of funding.
Chinese investors lead round for US influenza specialist
Ansun BioPharma, a US-based drug developer led by a former executive at healthcare-focused VC firms Caduceus Asia Partners and OrbiMed, has raised $80 million in Series B funding from a predominantly Chinese investor base.